Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment
Abstract Background Cholinesterase inhibitors (ChEIs) are an FDA-approved symptomatic treatment for patients with Alzheimer’s disease (AD). Its efficacy in patients with mild cognitive impairment (MCI), however, is controversial. Nonetheless, ChEIs have often been used in patients with MCI. From the...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2021-01-01
|
| シリーズ: | Alzheimer’s Research & Therapy |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s13195-020-00749-5 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|